Min Hou, Su Dong, Qing Kan, Meng Ouyang, Yun Zhang
{"title":"Is epinephrine still the drug of choice during cardiac arrest in the emergency department of the hospital? A meta-analysis.","authors":"Min Hou, Su Dong, Qing Kan, Meng Ouyang, Yun Zhang","doi":"10.2478/acph-2023-0022","DOIUrl":null,"url":null,"abstract":"<p><p>Epinephrine is the first-line emergency drug for cardiac arrest and anaphylactic reactions but is reported to be associated with many challenges resulting in its under- or improper utilization. Therefore, in this meta-analysis, the efficacy and safety of epinephrine as a first-line cardiac emergency drug for both out-of-hospital and in-hospital patients was assessed. Pertinent articles were searched in central databases like PubMed, Scopus, and Web of Science, using appropriate keywords as per the PRISMA guidelines. Retrospective and prospective studies were included according to the predefined PICOS criteria. RevMan and MedCalc software were used and statistical parameters such as odds ratio and risk ratio were calculated. Twelve clinical trials with a total of 208,690 cardiac arrest patients from 2000 to 2022 were included, in accordance with the chosen inclusion criteria. In the present meta-analysis, a high odds ratio (OR) value of 3.67 (95 % CI 2.32-5.81) with a tau<sup>2</sup> value of 0.64, a chi<sup>2</sup> value of 12,446.86, df value of 11, I2 value of 100 %, Z-value 5.53, and a <i>p</i>-value < 0.00001 were reported. Similarly, the risk ratio of 1.89 (95 % CI 1.47-2.43) with a tau<sup>2</sup> value of 0.19, chi<sup>2</sup> value of 11,530.67, df value of 11, I2 value of 100 %, Z-value of 4.95, and <i>p</i>-value < 0.000001. The present meta-analysis strongly prefers epinephrine injection as the first cardiac emergency drug for both out-of-hospital and in-hospital patients during cardiac arrest.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 3","pages":"325-339"},"PeriodicalIF":2.1000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/acph-2023-0022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Epinephrine is the first-line emergency drug for cardiac arrest and anaphylactic reactions but is reported to be associated with many challenges resulting in its under- or improper utilization. Therefore, in this meta-analysis, the efficacy and safety of epinephrine as a first-line cardiac emergency drug for both out-of-hospital and in-hospital patients was assessed. Pertinent articles were searched in central databases like PubMed, Scopus, and Web of Science, using appropriate keywords as per the PRISMA guidelines. Retrospective and prospective studies were included according to the predefined PICOS criteria. RevMan and MedCalc software were used and statistical parameters such as odds ratio and risk ratio were calculated. Twelve clinical trials with a total of 208,690 cardiac arrest patients from 2000 to 2022 were included, in accordance with the chosen inclusion criteria. In the present meta-analysis, a high odds ratio (OR) value of 3.67 (95 % CI 2.32-5.81) with a tau2 value of 0.64, a chi2 value of 12,446.86, df value of 11, I2 value of 100 %, Z-value 5.53, and a p-value < 0.00001 were reported. Similarly, the risk ratio of 1.89 (95 % CI 1.47-2.43) with a tau2 value of 0.19, chi2 value of 11,530.67, df value of 11, I2 value of 100 %, Z-value of 4.95, and p-value < 0.000001. The present meta-analysis strongly prefers epinephrine injection as the first cardiac emergency drug for both out-of-hospital and in-hospital patients during cardiac arrest.
肾上腺素是治疗心脏骤停和过敏反应的一线急救药物,但据报道,由于其使用不足或不当,导致许多挑战。因此,在本荟萃分析中,评估肾上腺素作为院外和院内患者一线心脏急救药物的有效性和安全性。在PubMed, Scopus和Web of Science等中央数据库中搜索相关文章,根据PRISMA指南使用适当的关键词。根据预先定义的PICOS标准纳入回顾性和前瞻性研究。采用RevMan、MedCalc软件,计算优势比、风险比等统计参数。根据选定的纳入标准,纳入了2000年至2022年12项临床试验,共208,690例心脏骤停患者。在本荟萃分析中,高比值比(OR)值为3.67 (95% CI 2.32-5.81), tau2值为0.64,chi2值为12,446.86,df值为11,I2值为100%,z值为5.53,p值< 0.00001。同样,风险比为1.89 (95% CI 1.47 ~ 2.43),其中tau2值0.19,chi2值11530.67,df值11,I2值100%,z值4.95,p值< 0.000001。本荟萃分析强烈倾向于肾上腺素注射作为心脏骤停期间院外和院内患者的第一种心脏急救药物。
期刊介绍:
AP is an international, multidisciplinary journal devoted to pharmaceutical and allied sciences and contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice. Topics covered are: analytics, biochemistry, biopharmaceutics, biotechnology, cell biology, cell cultures, clinical pharmacy, drug design, drug delivery, drug disposition, drug stability, gene technology, medicine (including diagnostics and therapy), medicinal chemistry, metabolism, molecular modeling, pharmacology (clinical and animal), peptide and protein chemistry, pharmacognosy, pharmacoepidemiology, pharmacoeconomics, pharmacodynamics and pharmacokinetics, protein design, radiopharmaceuticals, and toxicology.